225 related articles for article (PubMed ID: 32905646)
1. DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
Buelow DR; Anderson JT; Pounds SB; Shi L; Lamba JK; Hu S; Gibson AA; Goodwin EA; Sparreboom A; Baker SD
Clin Transl Sci; 2021 Jan; 14(1):137-142. PubMed ID: 32905646
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
Xu Q; Li Y; Jing Y; Lv N; Wang L; Li Y; Yu L
Int J Cancer; 2020 Mar; 146(5):1457-1467. PubMed ID: 31344264
[TBL] [Abstract][Full Text] [Related]
3. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
4. OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.
Drenberg CD; Gibson AA; Pounds SB; Shi L; Rhinehart DP; Li L; Hu S; Du G; Nies AT; Schwab M; Pabla N; Blum W; Gruber TA; Baker SD; Sparreboom A
Cancer Res; 2017 Apr; 77(8):2102-2111. PubMed ID: 28209616
[TBL] [Abstract][Full Text] [Related]
5. Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice.
Anderson JT; Hu S; Fu Q; Baker SD; Sparreboom A
Pharmacol Res Perspect; 2019 Dec; 7(6):e00534. PubMed ID: 31832201
[TBL] [Abstract][Full Text] [Related]
6. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
Oellerich T; Schneider C; Thomas D; Knecht KM; Buzovetsky O; Kaderali L; Schliemann C; Bohnenberger H; Angenendt L; Hartmann W; Wardelmann E; Rothenburger T; Mohr S; Scheich S; Comoglio F; Wilke A; Ströbel P; Serve H; Michaelis M; Ferreirós N; Geisslinger G; Xiong Y; Keppler OT; Cinatl J
Nat Commun; 2019 Aug; 10(1):3475. PubMed ID: 31375673
[TBL] [Abstract][Full Text] [Related]
7. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
[TBL] [Abstract][Full Text] [Related]
9. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
10. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
11. Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia.
Carraway HE; Malkaram SA; Cen Y; Shatnawi A; Fan J; Ali HEA; Abd Elmageed ZY; Buttolph T; Denvir J; Primerano DA; Fandy TE
Sci Rep; 2020 Jun; 10(1):10325. PubMed ID: 32587297
[TBL] [Abstract][Full Text] [Related]
12. Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs.
Ku Y; Park JH; Cho R; Lee Y; Park HM; Kim M; Hur K; Byun SY; Liu J; Lee YS; Shum D; Shin DY; Koh Y; Cho JY; Yoon SS; Hong J; Kim Y
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33762305
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia.
Zhou S; Liu P; Zhang H
Mol Med Rep; 2017 Jul; 16(1):281-287. PubMed ID: 28498449
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia.
Bhise NS; Elsayed AH; Cao X; Pounds S; Lamba JK
Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 31022985
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C).
Momparler RL; Côté S; Momparler LF
Leuk Res; 2013 Aug; 37(8):980-4. PubMed ID: 23660386
[TBL] [Abstract][Full Text] [Related]
17. Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.
Zhao W; Wei L; Tan D; Su G; Zheng Y; He C; Mao ZJ; Singleton TP; Yin B
PLoS One; 2014; 9(10):e109198. PubMed ID: 25314317
[TBL] [Abstract][Full Text] [Related]
18. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
[TBL] [Abstract][Full Text] [Related]
19. Effect of cytarabine and decitabine in combination in human leukemic cell lines.
Qin T; Youssef EM; Jelinek J; Chen R; Yang AS; Garcia-Manero G; Issa JP
Clin Cancer Res; 2007 Jul; 13(14):4225-32. PubMed ID: 17634552
[TBL] [Abstract][Full Text] [Related]
20. TBC1D16 predicts chemosensitivity and prognosis in adult acute myeloid leukemia (AML) patients.
Liu H; Chen P; Yang YL; Zhu KW; Wang T; Tang L; Liu YL; Cao S; Zhou G; Zeng H; Zhao XL; Zhang W; Chen XP
Eur J Pharmacol; 2021 Mar; 895():173894. PubMed ID: 33476656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]